Francois Xavier Mahon

Francois Xavier Mahon

UNVERIFIED PROFILE

Are you Francois Xavier Mahon?   Register this Author

Register author
Francois Xavier Mahon

Francois Xavier Mahon

Publications by authors named "Francois Xavier Mahon"

Are you Francois Xavier Mahon?   Register this Author

100Publications

3858Reads

8Profile Views

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.

Cancer 2019 Aug 29;125(16):2818-2828. Epub 2019 Apr 29.

Department of Anatomy, Cell Biology, and Physiological Sciences, American University of Beirut, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32130DOI Listing
August 2019

Novel analytical methods to interpret large sequencing data from small sample sizes.

Hum Genomics 2019 08 30;13(1):41. Epub 2019 Aug 30.

Laboratory of Mammary and Leukaemic Oncogenesis, Inserm U1218 ACTION, Bergonié Cancer Institute, University of Bordeaux, 146 rue Léo Saignat, bâtiment TP 4ème étage, case 50, 33076, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40246-019-0235-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717342PMC
August 2019

When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?

Clin Adv Hematol Oncol 2019 Feb;17(2):101-103

University of Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
February 2019

Treatment-Free Remission After Second-Line Nilotinib Treatment.

Ann Intern Med 2018 10;169(7):510

South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia (T.P.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/L18-0431DOI Listing
October 2018

Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.

Br J Haematol 2018 07 9;182(1):148-152. Epub 2017 May 9.

Laboratoire d'Hématologie, CHU de Brest and INSERM U1078, Université de Bretagne Occidentale, Brest, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14748DOI Listing
July 2018

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.

Br J Haematol 2018 01 19;180(1):24-32. Epub 2017 Oct 19.

Unicancer Center, Institut Bergonié and France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Bordeaux, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.14973
Publisher Site
http://dx.doi.org/10.1111/bjh.14973DOI Listing
January 2018

What is treatment free remission in chronic myeloid leukemia?

Oncotarget 2018 Jan 18;9(4):4279. Epub 2017 Dec 18.

Institut Bergonie Cancer Center, Department of Hematology, Universite Bordeaux, Bordeaux, Aquitaine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.23398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796972PMC
January 2018

What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?

Hematol Oncol 2017 Dec 19;35(4):420-423. Epub 2016 Jul 19.

Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, ACTION, INSERM U1218, University of Bordeaux, Bordeaux, Gironde, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2329DOI Listing
December 2017

Treatment-free remission in CML: who, how, and why?

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):102-109

Institut Bergonié, Cancer Centre, Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, INSERM U1218, University of Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142562PMC
December 2017

A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line.

Leuk Res 2017 10 31;61:44-52. Epub 2017 Aug 31.

University of Bordeaux, Bordeaux, France; Flow Cytometry Laboratory, CHU Haut-Lévêque, Pessac, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.08.014DOI Listing
October 2017

MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.

J Pathol 2017 07 29;242(3):347-357. Epub 2017 May 29.

Equipe thérapie génique, INSERM U 1035 Biothérapie des maladies génétiques et cancers, University of Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4908DOI Listing
July 2017

No, treatment for CML should not continue indefinitely.

Clin Adv Hematol Oncol 2017 Jun;15(6):489-494

University of Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
June 2017

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

J Clin Oncol 2017 Jan 31;35(3):298-305. Epub 2016 Oct 31.

Gabriel Etienne and François-Xavier Mahon, Institut Bergonié, Bordeaux; Joëlle Guilhot and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire (CHU) de Poitiers, Poitiers; Delphine Rea, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP); Bruno Varet, Hôpital Necker, AP-HP et Université Paris Descartes, Paris; Françoise Rigal-Huguet, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse; Franck Nicolini, Centre Hospitalier Lyon Sud, Pierre Bénite; Aude Charbonnier, Institut Paoli Calmette, Marseille; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Laurence Legros, Hôpital de l'Archet, Centre Hospitalier Universitaire de Nice, Nice; Martine Gardembas, CHU d'Angers, Angers; Viviane Dubruille, CHU Hôtel-Dieu, Nantes; Michel Tulliez, Hôpital Henri Mondor, Créteil; Marie-Pierre Noel, Hôpital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille; Jean-Christophe Ianotto, CHU Morvan, Brest; Bruno Villemagne, Centre Hospitalier Départemental La Roche-Sur-Yon, La Roche-Sur-Yon; Martin Carré, Hôpital Albert Michallon, CHU de Grenoble, Grenoble; Philippe Rousselot, Hôpital André Mignot, Le Chesnay; and François-Xavier Mahon, CHU de Bordeaux, INSERM U1218, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2914DOI Listing
January 2017

Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.

Cell Mol Life Sci 2016 12 19;73(24):4739-4748. Epub 2016 Jul 19.

Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate 74, 1200, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00018-016-2310-2DOI Listing
December 2016

Verification of a quantitative method: complete blood count by flow cytometry, the HematoFlow system (Beckman Coulter).

Ann Biol Clin (Paris) 2016 Oct;74(5):617-631

Laboratoire d'hématologie, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, Laboratoire de cytométrie en flux, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.

View Article

Download full-text PDF

Source
http://www.john-libbey-eurotext.fr/medline.md?doi=10.1684/ab
Publisher Site
http://dx.doi.org/10.1684/abc.2016.1181DOI Listing
October 2016

Deep molecular responses for treatment-free remission in chronic myeloid leukemia.

Cancer Med 2016 09 1;5(9):2398-411. Epub 2016 Jul 1.

Bergonié Cancer Institute, INSERM Unit 916, University of Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055167PMC
September 2016

Discontinuation of TKI therapy and 'functional' cure for CML.

Best Pract Res Clin Haematol 2016 09 20;29(3):308-313. Epub 2016 Oct 20.

Institut Bergonié, Cancer Centre, 229 cours de l'Argonne, 33076 Bordeaux, France; Laboratory of Mammary and Leukemic Oncogenesis: Genetic Diversity and Resistance to Treatment, INSERM U1218, University of Bordeaux, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.10.014DOI Listing
September 2016

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

J Natl Cancer Inst 2016 Jul 4;108(7). Epub 2016 Mar 4.

Affiliations of authors:Department of Health Policy and Management, Johns Hopkins University , Baltimore, MD (WVP); Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL; Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center , and Cecil G. Sheps Center for Health Services Research, University of North Carolina , Chapel Hill, NC (SBD); Department of Haematology, Hammersmith Hospital, Imperial College , London , UK (JFA); Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany; Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna , Bologna , Italy ; Department of Haematology and Oncology, University Hospital , Jena , Germany (EE); INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG); Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM); Department of Internal Medicine, Hematology and Oncology, University Hospital Brno , Brno , Czech Republic (JM); Department of Hematology and Oncology, University Hospital Leipzig , Leipzig , Germany (DN); Barbara Ann Karmanos Cancer Institute, Wayne State University , Detroit, MI (CAS); Department of Medicine, Weill Cornell Medical Center , New York, NY (RTS); Uppsala University , Uppsala , Sweden (BS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567PMC
July 2016

Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.

J Mol Diagn 2016 Jan 18;18(1):68-74. Epub 2015 Nov 18.

Hematology Laboratory, CHU de Bordeaux, Bordeaux, France; Leukemic Hematopoiesis and Therapeutic Targets Laboratory, Biothérapie des maladies génétiques et cancers, Université de Bordeaux, Bordeaux, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2015.07.007DOI Listing
January 2016

ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.

Int J Cancer 2015 Aug 21;137(3):698-709. Epub 2015 Jan 21.

Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.29407DOI Listing
August 2015

Discontinuation of tyrosine kinase therapy in CML.

Ann Hematol 2015 Apr 27;94 Suppl 2:S187-93. Epub 2015 Mar 27.

Laboratoire d'hématologie, CHU de Bordeaux, Bordeaux, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2320-4DOI Listing
April 2015

Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules.

Cancer 2015 Feb 24;121(4):490-7. Epub 2014 Oct 24.

INSERM Clinical Investigation Center 1402, Poitiers University, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29053DOI Listing
February 2015

A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.

PLoS One 2013 5;8(11):e78582. Epub 2013 Nov 5.

Université Bordeaux Segalen and INSERM U1035 Bordeaux, Bordeaux, France ; Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078582PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818406PMC
August 2014

EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells.

Anticancer Drugs 2014 Jul;25(6):624-32

Departments of aAnatomy, Cell Biology and Physiological Sciences bInternal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon cPharmacochemistry and Biomolecules Labs, Faculty of Pharmacy, Montpellier 1 University, Montpellier dHematology Lab and Blood Diseases Department, Bordeaux University Hospital, Victor Segalen University, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000084DOI Listing
July 2014

[Professor John M. Goldman 1938-2013].

Bull Cancer 2014 Mar;101(3):224

View Article

Download full-text PDF

Source
March 2014

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

J Clin Oncol 2014 Feb 9;32(5):424-30. Epub 2013 Dec 9.

Philippe Rousselot, Hôpital Mignot, Université Versailles Saint-Quentin-en-Yvelines, Versailles; Aude Charbonnier, Institut Paoli Calmette, Marseille; Pascale Cony-Makhoul, Hôpital d'Annecy, Pringy; Philippe Agape, Hôpital Felix Guyon-Centre Hospitalier Universitaire en France (CHU) de la Réunion, La Réunion; Franck E. Nicolini, Centre Hospitalier Lyon Sud, Pierre-Bénite; Bruno Varet, Hôpital Necker, Assistance Publique-Hopitaux de Paris (AP-HP) et Université Paris Descartes; Delphine Réa and Jean Michel Cayuela, Hôpital Saint-Louis, AP-HP, Paris; Martine Gardembas, CHU d'Angers, Angers; Gabriel Etienne and Josy Reiffers, Institut Bergonié; François-Xavier Mahon, Hôpital Haut-Levèque et Université Bordeaux Ségalen, Bordeaux; Lydia Roy, Joëlle Guilhot, and François Guilhot, Institut National de la Santé et de la Recherche Médicale (INSERM) Centres d'Investigation Clinique CHU de Poitiers, Poitiers; Martine Escoffre-Barbe, Centre Hospitalier Pontchaillou, Rennes; Agnès Guerci-Bresler, CHU Brabois Vandoeuvre, Nancy; Michel Tulliez, Hôpital Henri Mondor, AP-HP, Créteil; Stéphane Prost, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Institute of Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses; Marc Spentchian, Hôpital Mignot, Le Chesnay; and Jean Claude Chomel and Ali Turhan, INSERM U935, Université Poitiers et Paris Sud, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.5797DOI Listing
February 2014

Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

Clin Cancer Res 2014 Jan 28;20(2):310-22. Epub 2013 Oct 28.

Authors' Affiliations: Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Bordeaux and Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Biothérapies des maladies génétiques et cancers, Inserm U1035, Université Bordeaux Ségalen; and Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Institut Bergonié, Département d'Oncologie Médicale, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1988DOI Listing
January 2014

Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.

Fundam Clin Pharmacol 2013 Dec 31;27(6):690-7. Epub 2012 Oct 31.

Univ Bordeaux, F-33000, Bordeaux, France; INSERM U657, F-33000, Bordeaux, France; CHU Bordeaux, F-33000, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/fcp.12007DOI Listing
December 2013

Is going for cure in chronic myeloid leukemia possible and justifiable?

Hematology Am Soc Hematol Educ Program 2012 ;2012:122-8

Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux Cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2012.1.122DOI Listing
June 2013

Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest.

Leuk Res Treatment 2012 23;2012:861301. Epub 2012 Feb 23.

Laboratoire Hématopoïèse Leucémique et Cibles Thérapeutiques, INSERM U1035, Université Bordeaux Ségalen, 146 Rue Léo Saignat Bat TP 4e étage, 33076 Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/861301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504262PMC
December 2012

Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.

Haematologica 2012 Oct 14;97(10):1553-61. Epub 2012 Mar 14.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.haematologica.org/cgi/doi/10.3324/haematol.2012.0
Publisher Site
http://dx.doi.org/10.3324/haematol.2012.062844DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487556PMC
October 2012

Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.

Eur J Clin Invest 2012 Sep 1;42(9):1016-26. Epub 2012 May 1.

HRB Clinical Research Facility, National University of Ireland Galway and Trinity College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2362.2012.02675.xDOI Listing
September 2012

Curing chronic myeloid leukemia.

Curr Hematol Malig Rep 2012 Jun;7(2):103-8

Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, AP-HP, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-012-0117-2DOI Listing
June 2012

ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

Exp Hematol 2012 May 10;40(5):367-78.e2. Epub 2012 Jan 10.

Laboratoire d'Hématopoïèse Leucémique et Cibles Thérapeutiques, INSERM 1035, Université Bordeaux Segalen, Bordeaux Cedex, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0301472X120000
Publisher Site
http://dx.doi.org/10.1016/j.exphem.2012.01.004DOI Listing
May 2012

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.

Blood 2011 Aug 5;118(8):2211-21. Epub 2011 Jul 5.

Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Université Victor Ségalen, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-10-313692DOI Listing
August 2011

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.

Expert Rev Hematol 2010 Dec 9;3(6):665-73. Epub 2010 Nov 9.

HRB Clinical Research Facility, National University of Ireland, Galway & Trinity College, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.10.61DOI Listing
December 2010

A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.

Ther Drug Monit 2010 Aug;32(4):476-81

Département de Pharmacologie Clinique et Toxicologie, CHU de Bordeaux, Bordeaux, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0b013e3181d8b37fDOI Listing
August 2010

Remission in CML: is DNA useful?

Blood 2010 Aug;116(8):1192

Université Victor Ségalen Bordeaux 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-05-286310DOI Listing
August 2010